Proteome Sciences is pleased to announce the appointment of Jeremy Haigh as a director and CEO of the Company on 1st June 2016 as indicated in the press release to shareholders dated 18th May 2016. He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role.
Jeremy is an established leader in the biopharmaceutical sector with 30 years in clinical and operational research and development, principally at Merck and Amgen where most recently he was European Chief Operating Officer, R&D.
His basic training was in neuropharmacology and he has been significantly involved in healthcare policy and government affairs in the UK and Europe having served on the board of the BioIndustry Association (BIA), the European Federation of Pharmaceutical Industries (EFPIA) Research Directors Group, and the Association of the British Pharmaceutical Industry Innovation Board (ABPI). He is currently the Chairman of Cogent Skills Limited and a member of Imperial College Health Partners Advisory Council.
The following information regarding the appointment of Jeremy Rupert Michael Haigh, aged 55, is disclosed under Schedule 2(g) of the AIM Rules for Companies:
| Cogent SSC Ltd | Amgen Ltd BioIndustry Association Biovex Ltd Amgen Research (Munich) GmbH Onyx Pharmaceuticals (UK) Ltd |
|---|---|
| Current directorships and/or partnerships: | Former directorships and/or partnerships (within the last 5 years): |
Mr. Haigh does not currently hold any ordinary shares in the Company. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
With the news of his appointment, Jeremy Haigh commented,
“I am delighted to be joining Proteome Sciences at a time of tremendous opportunity. The challenge of developing more precise therapeutics coupled with growing patient expectations is creating a highly receptive environment for our enabling technologies and I look forward to working with the board and the entire team to realise this potential.”
Christopher Pearce added,
“As Chairman, I look forward to working closely with Jeremy and the executive team to help them exploit the considerable commercial opportunities arising in Precision Medicine from the outstanding proteomics platform Proteome Sciences has established to deliver truly personalised medicine.”